Published on December 21, 2012 at 10:22 AM
Nick Chapman, a policy analyst at Policy Cures, writes in a guest post on the Global Health Technologies Coalition's "Breakthroughs" blog about "the results of the latest G-FINDER survey on global funding of [research and development (R&D)] for neglected diseases." He discusses several findings and trends from the report, including the impact of the global financial recession on R&D funding; the relatively stable level of U.S. funding; the concentration of pharmaceutical company funding to "a limited number of diseases with some commercial overlap, such as dengue fever, bacterial pneumonia and meningitis, and tuberculosis (TB)"; the shift away from product development funding from public funders; and the effect of these trends on product development partnerships (PDPs) (Lufkin, 12/19).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.